Lila Levinson, PhD,  Science Writer—

Lila is a Science Writer at BioNews. She completed her PhD in neuroscience at the University of Washington, where she studied how the natural flexibility of the human brain can be used to promote recovery after injury. Previously, she has written about science for The Dallas Morning News and the University of Washington Computational Neuroscience Center. She enjoys exploring the Pacific Northwest and spending time with her cat, Fibonacci.

Articles by Lila Levinson, PhD

Unusual symptoms complicate Pompe disease diagnosis: Report

A newborn whose symptoms initially mimicked oxygen deprivation was ultimately diagnosed with Pompe disease, highlighting potential challenges in identifying the condition, according to a case report from Italy. This was an uncommon presentation, according to researchers, who described the child’s symptoms, which included an enlarged heart and weak…

Enrollment complete in Phase 1b trial of ABX1100 for LOPD

A Phase 1b clinical trial testing substrate reduction therapy ABX1100 in late-onset Pompe disease (LOPD) has completed enrollment, developer Aro Biotherapeutics said. This part of the trial (NCT06109948) investigates the medication’s safety, tolerability, and pharmacological profile in adults with LOPD. ABX1100 is given by intravenous (into-the-vein) infusion.

Pombiliti + Opfolda approved in Japan for adults with LOPD

Pombiliti + Opfolda (cipaglucosidase alfa/miglustat) has been approved for adults with late-onset Pompe disease (LOPD) by Japan’s Ministry of Health, Labour and Welfare (MHLW). “We are delighted that we will now be able to offer a compelling new treatment option to patients living with late-onset Pompe disease in…